Cargando…

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

BACKGROUND: Anakinra is the first interleukin-1 inhibitor to be used in clinical practice, and recent evidence showed that interleukin-1 plays a pivotal role in the pathogenesis of adult-onset Still disease (AoSD). However, data concerning efficacy with anakinra use in different clinical trials has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Dongsheng, Yang, Zhihai, Han, Shuyin, Liang, Xingguang, Ma, Kuifen, Zhang, Xingguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251663/ https://www.ncbi.nlm.nih.gov/pubmed/25473268 http://dx.doi.org/10.2147/DDDT.S73428

Ejemplares similares

Anakinra Hepatotoxicity in a Patient With Adult-Onset Still's Disease
por: Ahmed, Osman, et al.
Publicado: (2015)

Anakinra in Still’s disease: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review
por: Ortiz-Sanjuán, Francisco, et al.
Publicado: (2015)

Pulmonary Arterial Hypertension in Adult-Onset Still's Disease: Rapid Response to Anakinra
por: Campos, Marc, et al.
Publicado: (2012)

Anakinra in children and adults with Still’s disease
por: Vastert, Sebastiaan J, et al.
Publicado: (2019)

Correction to: Anakinra in Still’s disease: a profile of its use
por: Lyseng‑Williamson, Katherine A.
Publicado: (2018)

Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra
por: Kumar, Aswini, et al.
Publicado: (2016)

Adult-onset Still’s disease: Switch to atypical skin manifestations under anakinra therapy
por: Klapproth, Henning, et al.
Publicado: (2023)

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2021)

Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response
por: Vitale, Antonio, et al.
Publicado: (2019)

Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model
por: Ma, Kuifen, et al.
Publicado: (2017)

Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes
por: Vitale, Antonio, et al.
Publicado: (2020)

Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still’s disease: when dosage matters in overcoming secondary therapy resistance
por: Ajeganova, Sofia, et al.
Publicado: (2020)

Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
por: Ravasio, Roberto, et al.
Publicado: (2020)

Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease
por: Sota, Jurgen, et al.
Publicado: (2019)

Anti-Interleukin-1 Agents in Adult Onset Still's Disease
por: Giampietro, Cecilia, et al.
Publicado: (2012)

Efficacy of Anakinra in Pericarditis: A Systematic Review
por: Cheema, Ameer Haider, et al.
Publicado: (2022)

Efficacy of anakinra on rebound of multisystem inflammatory syndrome
por: Brisca, Giacomo, et al.
Publicado: (2022)

Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Hong, Dongsheng, et al.
Publicado: (2016)

Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review
por: Garg, Suchika, et al.
Publicado: (2019)

Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study
por: Laskari, Katerina, et al.
Publicado: (2011)

Anakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants
por: Green, Elys A., et al.
Publicado: (2022)

Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor – anakinra
por: Divithotawela, Chandima, et al.
Publicado: (2015)

Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis—A Pilot Study
por: Maier, André, et al.
Publicado: (2015)

EMA assessing safety of anakinra in adults with COVID-19
Publicado: (2021)

Post-infection immunocomplex glomerulonephritis and Legionnaires' disease in a patient with adult Still's disease during treatment with interleukin 1 receptor antagonist anakinra: a case report
por: Scholtze, Dieter, et al.
Publicado: (2011)

Different Features of Interleukin-37 and Interleukin-18 as Disease Activity Markers of Adult-Onset Still’s Disease
por: Nam, Seoung Wan, et al.
Publicado: (2021)

Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia
por: Ravasio, Roberto, et al.
Publicado: (2020)

The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis
por: MALIK, Hamna, et al.
Publicado: (2022)

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project
por: Thaler, Kylie, et al.
Publicado: (2009)

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
por: Pontali, Emanuele, et al.
Publicado: (2020)

A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19
por: Kharazmi, Amir Behnam, et al.
Publicado: (2021)

PW03-018 – Efficacy of Anakinra in recurrent pericarditis
por: Finetti, M, et al.
Publicado: (2013)

Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra
por: Peciuliene, Skaiste, et al.
Publicado: (2016)

Methylprednisolone/infliximab/anakinra: Lack of efficacy: case report
Publicado: (2021)

Anakinra/dexamethasone/etoposide: Lack of efficacy: case report
Publicado: (2021)

Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity
por: Chi, Huihui, et al.
Publicado: (2018)

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes
por: Bachove, Inessa, et al.
Publicado: (2014)

A Case Report on Adult-Onset Still’s Disease Successfully Treated With Tocilizumab: A Brief Review on its Safety and Efficacy
por: Nagalli, Shivaraj, et al.
Publicado: (2020)

Anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “The Valencia Experience”
por: Marvillet, I, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oqh5cab3tqu3kuq228ns94dql7